Articles published by Amylyx Pharmaceuticals, Inc.
![](https://mms.businesswire.com/media/20230803888287/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
Amylyx Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 10, 2023
August 03, 2023
Via Business Wire
Tickers
AMLX
![](https://mms.businesswire.com/media/20230712207804/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
![](https://mms.businesswire.com/media/20230622200968/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
![](https://mms.businesswire.com/media/20230615926630/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
![](https://mms.businesswire.com/media/20230606005053/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
![](https://mms.businesswire.com/media/20230530005232/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
![](https://mms.businesswire.com/media/20230511005805/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
Via Business Wire
Tickers
AMLX
![](https://mms.businesswire.com/media/20230504005006/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
Via Business Wire
Tickers
AMLX
![](https://mms.businesswire.com/media/20230420005326/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
![](https://mms.businesswire.com/media/20230413005192/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
![](https://mms.businesswire.com/media/20230411005241/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
Amylyx Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 11, 2023
Via Business Wire
Tickers
AMLX
![](https://mms.businesswire.com/media/20230313005731/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
Via Business Wire
Tickers
AMLX
![](https://mms.businesswire.com/media/20230308005080/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
Via Business Wire
Tickers
AMLX
![](https://mms.businesswire.com/media/20230307005368/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
![](https://mms.businesswire.com/media/20230207005048/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
Amylyx Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
February 07, 2023
Via Business Wire
Tickers
AMLX
![](https://mms.businesswire.com/media/20230202005258/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
Amylyx Pharmaceuticals Announces Completion of Enrollment in Global Phase 3 PHOENIX Trial of AMX0035 in ALS
February 02, 2023
Via Business Wire
Tickers
AMLX
![](https://mms.businesswire.com/media/20221122005013/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
Amylyx Pharmaceuticals to Participate in the Evercore ISI 5th Annual HealthCONx Conference
November 22, 2022
Via Business Wire
Tickers
AMLX
![](https://mms.businesswire.com/media/20221110006026/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
Amylyx Pharmaceuticals Reports Third Quarter 2022 Financial Results
November 10, 2022
Via Business Wire
Tickers
AMLX
![](https://mms.businesswire.com/media/20221103005256/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
Amylyx Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 10, 2022
November 03, 2022
Via Business Wire
Tickers
AMLX
![](https://mms.businesswire.com/media/20221011005927/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
![](https://mms.businesswire.com/media/20221006006078/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
Amylyx Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
October 06, 2022
Via Business Wire
Tickers
AMLX
![](https://mms.businesswire.com/media/20221004006112/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
Amylyx Pharmaceuticals Announces Launch of Public Offering
October 04, 2022
Via Business Wire
Tickers
AMLX
![](https://mms.businesswire.com/media/20220929005962/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for the Treatment of ALS
September 29, 2022
Via Business Wire
Tickers
AMLX
![](https://mms.businesswire.com/media/20220914005209/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
![](https://mms.businesswire.com/media/20220907006313/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
Amylyx Pharmaceuticals Announces FDA Advisory Committee Supports Approval of AMX0035 for the Treatment of ALS
September 07, 2022
Via Business Wire
Tickers
AMLX
![](https://mms.businesswire.com/media/20220907005824/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
![](https://mms.businesswire.com/media/20220831005780/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
![](https://mms.businesswire.com/media/20220811005026/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
Via Business Wire
Tickers
AMLX
![](https://mms.businesswire.com/media/20220802006047/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.